NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles (Data Paper) Cell Reports Year : 2022

NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma

Abstract

A long-standing question in the pancreatic ductal adenocarcinoma (PDAC) field has been whether alternative genetic alterations could substitute for oncogenic KRAS mutations in initiating malignancy. Here, we report that Neurofibromin1 (NF1) inactivation can bypass the requirement of mutant KRAS for PDAC pathogenesis. An in-depth analysis of PDAC databases reveals various genetic alterations in the NF1 locus, including nonsense mutations, which occur predominantly in tumors with wild-type KRAS. Genetic experiments demonstrate that NF1 ablation culminates in acinar-to-ductal metaplasia, an early step in PDAC. Furthermore, NF1 haploinsufficiency results in a dramatic acceleration of KrasG12D-driven PDAC. Finally, we show an association between NF1 and p53 that is orchestrated by PML, and mosaic analysis with double markers demonstrates that concomitant inactivation of NF1 and Trp53 is sufficient to trigger full-blown PDAC. Together, these findings open up an exploratory framework for apprehending the mechanistic paradigms of PDAC with normal KRAS, for which no effective therapy is available.
Fichier principal
Vignette du fichier
PIIS2211124722014942.pdf (9.46 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-04021544 , version 1 (09-03-2023)

Identifiers

Cite

Gopalakrishnan Ramakrishnan, Parash Parajuli, Pura Singh, Creighton Friend, Eric Hurwitz, et al.. NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. Cell Reports, 2022, 41 (6), pp.111623. ⟨10.1016/j.celrep.2022.111623⟩. ⟨inserm-04021544⟩
3 View
1 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More